<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / waste47powde / New</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 04 Sep 2020 10:01:57 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[Functions in order to finely control the immune response in vivo.]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=functions-in-order-to-finely-control-the-immune-response-in-vivo--6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=functions-in-order-to-finely-control-the-immune-response-in-vivo--6"><![CDATA[Functions in order to finely control the immune response in vivo.]]></source>
	<description><![CDATA[Functions in order to finely control the immune response in vivo. Among its cellular functions, TNFa is able to induce cytokines, chemokines, proliferation, and also cell death. The induction of pro-inflammatory versus death signals depends upon the molecular context of the responding cell, and specifically whether NFjB is involved [8]. Adding to the complexity of signaling, it is also reported th ]]></description>
	<pubDate>Fri, 04 Sep 2020 10:01:57 +0000</pubDate>
	<author>waste47powde</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=functions-in-order-to-finely-control-the-immune-response-in-vivo--6</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Thu, 03 Sep 2020 11:16:23 +0000</pubDate>
	<author>waste47powde</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Thu, 03 Sep 2020 11:15:11 +0000</pubDate>
	<author>waste47powde</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</guid>
</item>

</channel>
</rss>
